UCSF

Alumni

Name - email

Former position - years

Former project

Current position - bio

Shion Lim
contact
Postdoctoral Fellow
(2018-2020)
cCDCP1 mechanism and antibody engineering; anti SARS-CoV2 binders Scientist, Antibody Engineering at Genentech
bio - website
Amy Weeks
contact
Postdoctoral Fellow
(2013-2019)
Subtiligase engineering; TM-subtiigase for cell surface proteolysis Assistant Professor at University of Wisconsin-Madison
bio - website
Duy Nguyen
contact
Postdoctoral Fellow
(2013-2019)
Split CRISPR and AbTAC Senior Scientist at ArsenalBio
bio - website
Wentao Chen
contact
Postdoctoral Fellow
(2016-2019)
Myc-induced surfaceome in B-cells and prostate cancer Scientist at Amgen
bio - website
Lydia Zhang
contact
Specialist
(2016-2019)
Antibiome Center Graduate Student Researcher at University of California, Berkeley
bio - website
Zachary Hill
contact
Postdoctoral Fellow
(2012-2018)
NEDDylator for identifying kinase inhibitor targets; PTP1B tethering Cofounder and CSO of Soteria Biotherapeutics
bio - website
Michael Hornsby
contact
Antibiome Pipeline Director
(2012-2018)
Founded Antibiome Group and developed high through-put antibody engineering protocols, libraries, and robotics Associate Director of the Antibody Platform Technologies and Laboratory Automation group at Bristol Myers Squibb
bio - website
Sam Pollock
contact
Graduate Student
(2013-2018)
PhaNGS for multiplex cell surface profiling Scientist ar Freenome
bio - website
Alex Martinko
contact
Graduate Student
(2013-2018)
RAS-induced surfaceome; AbCIDs Co-Founder & Senior Director of Protein Engineering at Soteria Biotherapeutics
bio - website
Olivier Julian
contact
Postdoctoral Fellow
(2011-2017)
Mechanism of Cell killing by synthetic nanofibrils, N-terminomics Assistant Professor, University of Alberta
bio - website
Hai Tran
contact
Graduate Student
(2011-2017)
Thiocillin SAR and macrocycle dynamics; Met scan for oxaziridine labeling Senior Scientist, Protein Engineering at Soteria Biotherapeutics
bio - website
Ashley Smart
contact
Graduate Student
(2011-2017)
Light activated caspase to induce neurodegeneration Postdoc in Tom Clandinin's lab at Stanford
bio - website
Yun (Kurt) Mou
contact
Postdoctoral Fellow
(2015-2017)
pTyr antibody phage; Myc-induced surfaceome Assistant research fellow at the Institute of Biomedical Sciences at Academia Sinica
bio - website
Nathanael Gabler
contact
Specialist
(2016-2017)
Antibiome Center Medical Copywriter at Copy & Art Advertising
bio - website
Paul Marinec
contact
Postdoctoral Fellow
(2011-2016)
Antibodies to mutant KRAS Senior Scientist, Reflexion Pharmaceuticals
bio - website
Julia Seaman
contact
Graduate Student
(2011-2016)
Cleavage specificity of caspases; Degrabase Healthcare consultant at Prescient Healthcare Group
bio - website
Peter Lee
contact
Postdoctoral Fellow
(2014-2016)
AbCIDs; caspase structure Principal Scientist at Bristol Myers Squibb. Protein and antibody engineering of biotherapeutic molecules
bio - website
Marja Tarr
contact
Administration
(2006-2016)
  Retired
bio - website
Juan Diaz
contact
Postdoctoral Fellow
(2008-2015)
split kinases (sKIN); Abl kinase substrates Group Leader, Antibody Discovery at Xencor where his group is designing new immunotherapies and check point blockers
bio - website
Charles Morgan
contact
Graduate Student
(2008-2015)
SNIPer and sKIN activation of substrates bio - website
Allison Dork
contact
Lab Manager
(2008-2015)
lab manager Field Sales Manager for Life Sciences at VWR
bio - website
Justin Rettenmaier
contact
Graduate Student
(2010-2015)
Kinase activators for PDK1; Tethering allostery Associate Director at Jnana Therapeutics
bio - website
Benjamin Spangler
contact
Graduate Student
(2012-2015)
Iron activated trioxylanes for Myc-driven cancers Scientist II, Delivery Solutions
bio - website
Tet Matsuguchi
contact
Robotic Specialist
(2012-2015)
Robotics specialist Senior Manager, Tech Transfer at Guardant Health
bio - website
Brian Lee
contact
Specialist
(2013-2015)
Proteome-Antibody Center Senior VP at Visolis, Inc.
bio - website
JT Koeber
contact
Postdoctoral Fellow
(2008-2014)
Antibodies to pSer/pThr; scFab Senior Scientist at Genentech, Department of Antibody Engineering
bio - website
Jason Porter
contact
Postdoctoral Fellow
(2009-2014)
Split phosphatases; PTEN Health Science Specialist, Bureau For Global Health, U.S. Agency for International Development
bio - website
Min Zhuang
contact
Postdoctoral Fellow
(2009-2014)
NEDDylator proximity tagger; Caspase-6 substrates Assistant Professor, Shanghai Tech Universtiy
bio - website
Nathan Thomsen
contact
Postdoctoral Fellow
(2010-2014)
Antibody activators of pro-caspase; allosteric activation Director in Protein Therapeutics Department at Gilead Sciences
bio - website
Arun Wiita
contact
Hem/OncClinical Fellow
(2011-2014)
Caspase biomarkers; Multi-omics of cytotoxics Assoc. Professor in Residence Laboratory Medicine
bio - website
Sean Hudson
contact
Postdoctoral Fellow
(2013-2014)
Tether scan Artist
bio - website
Julie Zorn
contact
Graduate Student
(2006-2012)
Small molecule caspase activators; nanofibrils Senior Research Investigator 1 at Bristol Myers Squibb
bio - website
Emily Crawford
contact
Graduate Student
(2006-2012)
Evolution of caspase sites; Degrabase Scientific Advisor at The Production Board
bio - website
Kazutaka Shimbo
contact
Postdoctoral Fellow
(2010-2012)
N-terminomics; drug-induced apoptotic substrates Scientist at Ajinomoto
bio - website
Jack Sadowski
contact
Postdoctoral Fellow
(2006-2011)
Kinase allosteric tethering activators/inhibitors Senior Scientist in Protein Chemistry department at Genentech
bio - website
David P. Wildes
contact
Postdoctoral Fellow
(2006-2011)
Seerum N-terminomics Scientist at Revolution Medicines
bio - website
Nicholas Agard
contact
Postdoctoral Fellow
(2007-2011)
N-terminomics of inflammatory caspases Senior Scientist at Genentech
bio - website
Christopher McClendon
contact
Graduate Student
(2007-2011)
Small molecule discovery for challenging sites Senior Principal Scientist, Medicine Design Discovery Network, Pfizer
bio - website
Daniel Gray
contact
Graduate Student
(2007-2011)
split TEV (SNIPer), role of apoptotic caspases bio - website
Gerald Hsu
contact
Hem/OncClinical Fellow
(2009-2011)
Drug-induced caspase substrates; caspase biomarkers Associate Clinical Professor of Medicine, UCSF. Fellowship program director, Division of Hematology/Oncology.
bio - website
Sami Mahrus
contact
Postdoctoral Fellow
(2005-2010)
N-terminomics Principal Data Scientist, RWD Oncology at Genentech
bio - website
Dennis Wolan
contact
Postdoctoral Fellow
(2005-2009)
Small molecule caspase activators Associate Professor at The Scripps Research Institute
bio - website
JunJun Gao
contact
Postdoctoral Fellow
(2005-2009)
Conformationally selective antibody selections Senior Associate Director, External Innovation at Boehringer-ingelheim
bio - website
Yingfeng Qiao
contact
Postdoctoral Fellow
(2005-2009)
RAS Tethering Pharmacist
bio - website
Debajyoti Datta
contact
Graduate Student
(2005-2009)
Caspase-1 allosteric hot wires Hematology/Oncology Fellow at UCSF
bio - website
Huy Nguyen
contact
Hem/OncClinical Fellow
(2007-2009)
Drug-induced caspase substrates Hematologist and medical oncologist at Palo Alto Medical Foundation
bio - website
Justin Scheer
contact
Postdoctoral Fellow
(2003-2006)
Allosteric Tethering on inflammatory caspases Vice President, Gene Therapy and Gene Delivery Platforms
bio - website
Hikari Yoshihara
contact
Postdoctoral Fellow
(2003-2006)
Subtiligase tags for N-terminomics Scientist at EPFL (École polytechnique fédérale de Lausanne)
bio - website
Jeanne Hardy
contact
Postdoctoral Fellow
(2002-2005)
Allosteric Tethering on apoptotic caspases Faculty member in the Department of Chemistry at Umass Amherst
bio - website
Jack Nguyen
contact
Postdoctoral Fellow
(2000-2003)
Apoptosis activators; allosteric tethering Chief Scientific Officer at Dyad Therapeutics, Inc.
bio - website
Chris Thanos
contact
Postdoctoral Fellow
(2000-2003)
IL-2 mimetics; hot-spot analysis CEO | Cofounder at Actym Therapeutics, Inc.
bio - website
Liz Buck
contact
Postdoctoral Fellow
(2001-2003)
Tethering on GPCR, C5A receptor Co-Founder, Executive Vice President, Discovery & Translational Sciences at Black Diamond Therapeutics.
bio - website
Michelle Arkin
contact
Postdoctoral Fellow
(1997-2000)
Catalytic antibody mutagenesis and phage display Professor and the department Chair of Pharmaceutical Chemistry at UCSF
bio - website
Dan Erlanson
contact
Postdoctoral Fellow
(1997-2000)
Cyclic peptide synthesis, tethering VP of Chemistry, Frontier Medicines
bio - website
Warren DeLano
contact
Graduate Student
(1994-1999)
Fc peptide phage; mimetics; PyMol Deceased
bio - website
Greg Weiss
contact
Postdoctoral Fellow
(1996-1999)
Phage display, gene8 display, Professor of Chemistry, Molecular Biology & Biochemistry, and Pharmaceutical Sciences at UCI
bio - website
Sachdev Sidhu
contact
Postdoctoral Fellow
(1996-1999)
Phage display, turbo ala-scanning, libraries Professor at University of Toronto
bio - website
Brian Cunningham
contact
Scientist
(1984-1998)
hGH mutagensis, phage display, hot-spots Enjoying life in Thailand and San Mateo
bio - website
Germain Fuh
contact
Scientist
(1985-1998)
hGH and hPRL receptor antagonists Director of the Antibody and Protein Engineering group in 23andMe
bio - website
Andrew Braisted
contact
Postdoctoral Fellow
(1994-1998)
Protein A minimization; tethering Deceased
bio - website
Shane Atwell
contact
Graduate Student
(1993-1997)
hGH receptor and subtiligase phage display Research Advisor, Bio technology discovery & research at Lily
bio - website
Manuel Baca
contact
Postdoctoral Fellow
(1994-1997)
Phage display for humanization, Avastin Senior Director and Head of Biologics Discovery, Gilead Sciences
bio - website
Ken Pearce
contact
Postdoctoral Fellow
(1994-1996)
hGH binding thermodynamics and cell activity Research Professor at UNC Chapel Hill
bio - website
Tim Clackson
contact
Postdoctoral Fellow
(1992-1995)
Hot spots on hGH and hGH receptor President and CTO at Xilio Therapeutics
bio - website
Marcus Ballinger
contact
Postdoctoral Fellow
(1993-1995)
Furilisin and substrate phage Director of Clinical Science at Genentech
bio - website
Lei Jin
contact
Graduate Student
(1989-1994)
Antibody epitope discovery, ala-scanning CEO of Gensci
bio - website
Dave Matthews
contact
Postdoctoral Fellow
(1991-1994)
Substrate phage Consultant and Wine Maker
bio - website
Tom Chang
contact
Postdoctoral Fellow
(1991-1994)
Subtiligase engineering, bioconjugations Staff Scientist/Group Leader in Protein Chemistry at Nektar Therapeutics
bio - website
Dave Jackson
contact
Postdoctoral Fellow
(1992-1994)
Subtiligase and synthetic protein synthesis Pharmaceutical & Biologics Consultant
bio - website
Henry Lowman
contact
Postdoctoral Fellow
(1989-1992)
Phage Display, hGH affinity optimization Full time consultant on biologics R&D
bio - website
Steve Bass
contact
Postdoctoral Fellow
(1988-1991)
Phage Display, hGH receptor Retired
bio - website
Scott Braxton
contact
Postdoctoral Fellow
(1989-1991)
subtilisn mutagenesis and engineering Photographer and Real estate
bio - website
Paul Carter
contact
Postdoctoral Fellow
(1986-1990)
subtilisin engineering, substrate-assisted catalysis Genentech Fellow in the Antibody Engineering Department at Genentech and President of the Antibody Society.
bio - website
Lars Abrahmsen
contact
Postdoctoral Fellow
(1988-1990)
subtiligase and subtilisin engineering Chief Scientific Officer, Aprea Therapeutics
bio - website
Dave Powers
contact
Senior Research Assoc
(1983-1986)
subtilisin engineering, cassette mutagenesis Senior Principal Research Scientist at Abbvie Biotherapeutics
bio - website

Shion Lim
Present Position: Scientist, Antibody Engineering, Genentech. Description: Shion is currently a Scientist in the Department of Antibody Engineering at Genentech. She is excited about creatively applying protein and antibody engineering techniques to design biotherapeutics against challenging targets and proteoforms. She is also interested in understanding and leveraging antibody biophysical properties and exploring how computational tools can expand the scope of drug discovery. Shion is looking forward to growing her career and pushing these research areas forward in an invigorating and collaborative place like Genentech. 

Amy Weeks
Assistant Professor at University of Wisconsin-Madison

Duy Nguyen
Senior Scientist at ArsenalBio

Wentao Chen
Scientist, Amgen. I am currently engineering antibody therapeutics with the help of display technologies. 

Lydia Zhang
Graduate Student Researcher at University of California, Berkeley

Zachary Hill
Zach is cofounder and CSO of Soteria Biotherapeutics, a biotech start-up spun out of the Wells lab in 2018. Soteria is leveraging AbCID technology to development next-generation bispecifics antibodies for the treatment of cancer. 

Michael Hornsby

Sam Pollock
Scientist, Freenome. Using proteomics, automation, and machine learning, our work focuses on enabling confident early cancer detection

Alex Martinko
Co-Founder & Senior Director of Protein Engineering at Soteria Biotherapeutics

Olivier Julian
Assistant Professor, University of Alberta. Using functional proteomics approaches (including subtiligase!), our lab focus on characterizing how proteases and their substrates play critical roles in cell death and cell differentiation, viral infections, cardiovascular diseases and neurodegeneration.

Hai Tran
I am interested in using protein engineering to develop next generation therapeutics. At Denali, I developed and optimized multiple platform technologies to transport therapeutic antibodies, enzymes, proteins, and oligonucleotides across the Blood-Brain Barrier for the treatment of neurodegenerative diseases. At Soteria, I am helping to develop the next generation of conditionally active bispecific T-cell engagers to treat cancer patients with solid tumors.

Ashley Smart
I'm using fruit flies to map behavior to neural circuits. I'm specifically interested in how the brain can keep track of intervals of time.

Yun (Kurt) Mou
Assistant research fellow at the Institute of Biomedical Sciences at Academia Sinica. we are working on GPCRs now using A-GPS

Nathanael Gabler

Paul Marinec
Senior Scientist, Reflexion Pharmaceuticals. I am currently directing Reflexion’s protein engineering efforts to create an exciting new class of therapeutics composed entirely of D-amino acids. Our mirror-image proteins are 30X smaller than traditional antibody therapeutics, enabling better tissue and tumor penetration, while being completely non-immunogenic and resistant to degradation by proteases. We are close to submitting our first IND with the FDA for our lead VEGF program, and have several immuno-oncology programs in late stages of development as well

Julia Seaman
After graduating UCSF, I joined Prescient Healthcare Group to work as a healthcare consultant working with biotech and pharma companies to help them define their product strategy and assess their competitive market. 

Peter Lee
Principal Scientist at Bristol Myers Squibb. Protein and antibody engineering of biotherapeutic molecules

Marja Tarr

Juan Diaz
Group Leader, Antibody Discovery at Xencor

Charles Morgan
Lets hold off on updating my information regarding Sydney until it becomes official. I’ll send you a link and description for the alumni webpage in a month or two.

Allison Dork
Field Sales Manager for Life Sciences at VWR

Justin Rettenmaier
Associate Director at Jnana Therapeutics. After leaving Jim's lab, I was a postdoc studying neurodegenerative disease with the late Susan Lindquist at the Whitehead Institute. I was then recruited as the sixth employee at the drug discovery startup Jnana Therapeutics, where we focus on small molecule therapeutics targeting the SLC family of metabolite transporters. I currently co-lead the technology development group (chemical biology and high-throughput screening) as well as the immunology discovery group.

Benjamin Spangler
Scientist II, Delivery Solutions. Since leaving UCSF I pursued an industrial post-doc at NIBR in Emeryville developing novel tools and assays to interrogate sub-cellular compound exposure in Gram-negative bacteria. From there I moved to a medicinal chemistry position at Exelixis before transitioning to my current role at BioMarin where I am exploring and developing new methods for delivering drug payloads to target tissues.

Tet Matsuguchi
Senior Manager, Tech Transfer at Guardant Health

Brian Lee

JT Koeber

Jason Porter
Health Science Specialist, Bureau For Global Health, U.S. Agency for International Development. At USAID Jason has worked in a variety of positions with a focusing on building the capacity of local development actors to realize their own development goals. In the U.S. Global Development lab he managed a portfolio of 50+ small research grants across Africa and Central Asia and developed programs to build clinical research and medical training capacity in post-Ebola Liberia. In the Bureau for Global Health he support the President’s Emergency Plan for AIDS Relief (PEPFAR) supporting the capacity development for local clinical care providers and host country governments in East and Southern Africa

Min Zhuang
Assistant Professor, Shanghai Tech Universtiy. Currently, my research interests are in two areas: 1) Develop new proximity labeling tools for protein-protein interaction study; 2) Role of protein posttranslational modification is peroxisome homeostasis.

Nathan Thomsen
After my Postdoc in the Wells Lab I joined the Biologics group at Gilead where I helped establish fundamental protein and antibody engineering capabilities.  During my time at Gilead I have had the opportunity to lead or support multiple research and development programs from inception to IND, and I have also participated in external diligence efforts leading to the successful in-licensing of clinical stage therapeutics.  I now lead a functional area that utilizes single B-cell cloning, multiple display technologies and structure-based design to discover and optimize fit-for-purpose protein therapeutics that address unmet needs across multiple therapeutic areas.  

Arun Wiita
After finishing my post-doc with Jim, in 2014 I became a faculty member in the Dept. of Laboratory Medicine at UCSF, where 25% of my time is devoted to clinical work in molecular pathology and the remainder to running my research group. Our research lab is interested in using proteomic methods and cellular engineering to develop new therapies to treat poor-prognosis and drug-resistant forms of blood cancers

Sean Hudson

Julie Zorn
Julie was a post-doctoral fellow with John Kuriyan and then joined Genentech in Protein Sciences. She left Genentech to become a Senior Research Investigator in the Protein Sciences group at BMS.

Emily Crawford
after graduating from the Wells lab I did a postdoc with Joe DeRisi where I began to focus on technology development for infectious disease diagnostics. After that I spent 4 years leading a team at the CZ Biohub, including building and running the Biohub's COVID19 PCR testing facility in 2020. I'm now working as a Scientific Advisor for early-stage startups at The Production Board

Kazutaka Shimbo
Scientist at Ajinomoto. Proteomics, protein characterization, mass spectrometry. (Ajinomoto is doing the business for Biopharma companies to provide protein manufacturing or modifications, like ADCs)

Jack Sadowski
After an ~2 year stint at Carmot Therapeutics, contributing to the development of the small molecule lead-finding technology Chemotype Evolution, Jack joined the Protein Chemistry department at Genentech in 2013 where he is currently a Senior Scientist. The scientific focus of Jack's lab at Genentech has been the invention of bioconjugation chemistries and methods for application in drug delivery with a focus on antibody-drug conjugates (ADCs).

David P. Wildes
I'm still at RevMed (5 years!). It's been a crazy ride, and lots of programs are starting to really take off.  Our SHP2 inhibitor continues to show promise after completing Phase 1 this year, and our mTORC1 inhibitor (based on Kevan's RapaLink1 technology) will be entering the clinic shortly-- I'm also putting finishing touches on revisions for a Nature Chem Bio manuscript on the mTORC1 program over the break, and hopefully that will be in print early next year.  And the Warp Drive technology continues to exceed all expectations.  There'll be some updates announced at JPM in a couple of weeks, but we showed data last fall for an orally bioavailable KRAS G12D inhibitor that absolutely crushes xenograft tumors in mice.  I've built and been leading a biochemistry and chemical biology group with some really fantastic scientists.  My counterpart who heads cell and systems biology is transferring internally to another position at the start of the year, so I'll be leading the whole in vitro biology team soon, which is bigger than the company was when I started.  It's amazing to see the organization grow and evolve like this.  

Nicholas Agard
Senior Scientist at Genentech

Christopher McClendon
Senior Principal Scientist, Medicine Design Discovery Network, Pfizer

Daniel Gray
In between job. will update us in a few weeks

Gerald Hsu
Associate Clinical Professor of Medicine, UCSF. Fellowship program director, Division of Hematology/Oncology. Since leaving the Wells lab, I finished medical training and stayed close to home at UCSF and the San Francisco VA where I practice hematology/oncology and serve as program director for the fellowship program. In the latter role, I hope to provide opportunities to train the future Jim Wells' of the world.

Sami Mahrus
After his postdoc, Sami joined the Oncology Biomarker Development group at Genentech, developing and implementing pharmacodynamic, predictive, and companion diagnostic biomarker strategies for selected clinical programs in the Genentech/Roche pipeline. More recently, Sami has been with the Real World Data Oncology group at Genentech, leveraging data from real-world healthcare settings, such as those from Flatiron Health, for insights and evidence supporting the Genentech/Roche oncology portfolio

Dennis Wolan
Dennis Wolan just accepted a position as X at Genentech. He was an Assistant Professor of Department of Integrative Structural and Computational Biology at Scripps from 2009-2020 studying hydrolases, particularly proteases, in the human miocrobiome using proteomics and functinal genomic. He developed new classes of protease inhibitors and substrate technologies.

JunJun Gao

Yingfeng Qiao

Debajyoti Datta
Hematology/Oncology Fellow at UCSF

Huy Nguyen
After leaving the Wells lab in 2009, I spent the next 10 years in Honolulu, HI in full time clinical practice as a hematologist and medical oncologist.  In 2019, I returned to the Bay Area where I now practice at the Palo Alto Medical Foundation in Mountain View and Sunnyvale.

Justin Scheer
Prior to JNJ, Justin was Director of Biologics and Protein Engineering at Boeringer Ingleheim. After leaving the Wells lab 2006 he joined the Protein Sciences Group at Genentech ultimately rising to Senior Scientist and among other achievements developed new approaches to expression of bi-specific antibodies.

Hikari Yoshihara
Scientist at EPFL (École polytechnique fédérale de Lausanne) Laboratory of functional and metabolic engineering

Jeanne Hardy
I have been a faculty member in the Department of Chemistry at Umass Amherst since leaving Jim’s lab at Sunesis Pharmaceuticals in 2005.  My lab focuses on understanding structure and regulation of biomedical important proteases, like caspases and viral proteases. In particular we are interested in exploiting allosteric sites and exosites therapeutically. I also serve as the Director of the UMass Biotech Training Program.

Jack Nguyen
Stating in 2020, I’ve been working on a new startup company focusing on developing drugs for Parkinson’s and other CNS diseases.  I’ve recruited David O’Reilly as a founder (as you might recall, he was President of Catalyst early on and we’ve stayed friends); the other founder is Jim Surmeier, chair of the Dept. of Physiology at Northwestern.  The company is based on Jim’s work focusing on a calcium channel whose activity is central to a number of CNS disorders, and we have a license to IP on the target and compounds from Northwestern.  We’ve been working hard to shore up the IP and development plan, and will be hitting the (virtual) road to talk to investors next month. 

Chris Thanos
President, CEO, and Cofounder of Actym Therapeutics. Dr. Thanos has over 26 years of R&D experience, including 20 years in the biotechnology industry.Previously, Dr. Thanos was appointed Head of Biotherapeutics Discovery Research at Halozyme (NASDAQ: HALO), leading Molecular Biology / Protein Engineering, Immunology, and Cell Biology Groups at the company toward FDA approval of HYQVIA®, the ENHANZE® subcutaneous therapeutic delivery platform. Before HALO, Dr. Thanos was Head of Protein Engineering at Sutro Biopharma (NASDAQ:STRO). Prior to Sutro, Dr. Thanos co-founded Catalyst Biosciences (NASDAQ:CBIO), where he participated in raising venture capital, and helped to establish the company’s therapeutic technology platform. Earlier in his career, Dr. Thanos was a National Cancer Institute Postdoctoral Fellow under Professor Jim Wells at UCSF and Sunesis (NASDAQ:SNSS). He earned a Ph.D. in Molecular Biology and Biochemistry from UCLA where he was an NIH Chemistry / Biology Interface Predoctoral Fellow with Jim Bowie.

Liz Buck
She has more than 15 years of experience in oncology therapeutics in biotechnology and large pharmaceutical companies.  Liz was Assistant Director of Advanced Preclinical Pharmacology at OSI Pharmaceuticals, where she led discovery and translational research to advance a series of oncology programs to clinical development. Liz earned a Ph.D. in Cellular and Molecular Biology from New York University/Mount Sinai School of Medicine and completed postdoctoral work with Jim Wells at Sunesis Pharmaceuticals. She received her undergraduate degree in Physics from the University of New Hampshire.

Michelle Arkin
I was a Damon Runyon postdoctoral fellow in Jim’s lab from 1997-1998 at Genentech and Sunesis.  I was a scientist at Sunesis and worked with an amazing team to develop small-molecule inhibitors of protein-protein interactions using fragment-based drug discovery.  After nine years in drug discovery and development at Sunesis, I moved to UCSF to help Jim and Adam Renslo lead the Small Molecule Discovery Center.  I am also a Professor and the department Chair of Pharmaceutical Chemistry, where I run a research group dedicated to chemical biology and drug discovery for new and challenging targets. Michelle was a Damon Runyon postdoctoral fellow in Jim’s lab from 1997-1998 at Genentech and Sunesis. She then spent nine years at Sunesis, first in discovery of protein-protein interaction inhibitors and then as Associate Director of Cell Biology. In 2007, she moved to UCSF to join the Small Molecule Discovery Center and direct run a research group dedicated to chemical biology and drug discovery for new and challenging targets. She recently became Chair of the department of Pharmaceutical Chemistry.

Dan Erlanson
VP of Chemistry, Frontier Medicines.Dan moved from Genentech to Sunesis Pharmaceuticals when Jim founded the company in 1998, and he has been pursuing fragment-based drug discovery ever since. After Sunesis Dan co-founded Carmot Therapeutics, and has since moved to Frontier Medicines.

Warren DeLano

Greg Weiss
Position: Professor of Chemistry, Molecular Biology & Biochemistry, and Pharmaceutical Sciences at UCI. Short description: Greg’s lab applies diverse techniques from biophysics, protein engineering, and chemical biology to dissect protein function. He has co-founded two biotech companies and has graduated >100 students and postdoctoral fellows from his lab.

Sachdev Sidhu
Dr. Sachdev Sidhu is an expert in phage display technology and structure-based and combinatorial protein engineering. In 2008, after spending a decade as a principal investigator in the Department of Protein Engineering at Genentech, Inc., Dr. Sidhu joined the University of Toronto to start his academic lab. At Genentech, Dr. Sidhu led the development of phage-displayed synthetic antibody libraries that have since proven to be a rich source of valuable reagents for basic research and potential therapeutics. In addition to antibody engineering, Dr. Sidhu has extensive experience with phage display of other diverse polypeptides, including peptides, peptide-binding domains, hormones and antibody mimics.

Brian Cunningham

Germain Fuh
Director of the Antibody and Protein Engineering group in 23andMe, Therapeutics Unit where we are developing medicine to unmet medical needs. We discover drug targets using the large genetic information available to us. 

Andrew Braisted

Shane Atwell
Research Advisor, Bio technology discovery & research at Lily. Shanes primary job is the discovery and engineering of antibody therapeutics for autoimmune diseases. He is also active in developing new technologies related to e g. bispecifics, anti body drug conjugates and anti body crystallization.

Manuel Baca
Senior Director and Head of Biologics Discovery, Gilead Sciences. Working as a postdoc in the Wells lab was a highlight of my early career and a key influence in directing me toward a career of discovering and developing protein-based therapeutics. Two decades, two continents and two US coasts later, I’m back in the vicinity of where this began and currently lead the biotherapeutics discovery team at Gilead Sciences.

Ken Pearce

Tim Clackson
Dr. Clackson is President of Xilio and Chief Technology Officer. Prior to Xilio, he was President of R&D and Chief Scientific Officer at ARIAD Pharmaceuticals. Earlier in his career, Dr. Clackson was a postdoctoral fellow with Dr. James A. Wells in the Department of Protein Engineering at Genentech, where his studies on growth hormone receptor defined the now-established “hot spot” paradigm for how proteins interact. He received his Ph.D. in Biology from Cambridge University for research conducted under Dr. Greg Winter at the MRC Laboratory of Molecular Biology into antibody engineering and the development of antibody phage display technology.

Marcus Ballinger
I spent several years as a drug discovery biochemist at Chiron and Sunesis, and at Exelixis I made a major career shift by moving into oncology drug clinical science. I'm now a Director of Clinical Science at Genentech where I've been working on cancer immunotherapy trials in melanoma and lung cancer since 2012. 

Lei Jin
Co-Counder and CEO Gene Sciences, China

Dave Matthews

Tom Chang
Staff Scientist/Group Leader in Protein Chemistry at Nektar Therapeutics. After leaving Jim’s lab at Genentech, I worked at Roche using molecular and genomic approaches to identify new targets for neurobiology. I then moved onto KaloBios to develop several antibodies and helped the company go public. Currently, I am at Nektar engineering cytokines for oncology and autoimmune diseases.

Dave Jackson
After leaving Jim's lab in protein engineering, I accepted a scientist position in the medicinal chemistry department where I worked on numerous small molecule and biologics programs. I also led the ADC discovery team from 2003-2006. I left Genentech in 2007 to work as a full time dad, and resumed my career 4 years later as the head of chemistry at Igenica in Burlingame. In 2016 I was recruited by Bolt Biotherapeutics to lead their ADC discovery effort. I was the 3rd employee and helped build the company from the ground up. I left Bolt in 2019 and have been consulting ever since.

Henry Lowman
Henry is currently consulting full-time on biologics R&D.  After 3 exciting years as a postdoc in the Wells Lab at Genentech, he continued work in therapeutic antibody engineering, including discovery and early development, and moved to management roles at Genentech, CytomX, and Triphase

Steve Bass
DuPont Pioneer. Now retired

Scott Braxton

Paul Carter
Paul Carter is currently a Genentech Fellow in the Antibody Engineering Department at Genentech and President of the Antibody Society. Paul's research passion is the quest for breakthrough antibody-based therapeutics that transform the lives of patients. Current research projects include making previously intractable targets druggable with antibodies, intracellular delivery of proteins and preclinical immunogenicity risk prediction for engineered protein therapeutics.

Lars Abrahmsen
Lars Abrahmsén, Postdoctoral Fellow, Subtiligase, Chief Scientific Officer, Aprea Therapeutics. I’ve been in the pharma industry during all of the 30 years since my postdoc. The upside has been the opportunity to work with many different types of projects spanning from protein engineering to pharmaceutical development of antibodies, small molecules and radio conjugates, involving projects from exploratory phase to phase III clinical studies. This has involved collaborations with experts in many disciplines and many great scientists. The downside has been to have to leave an interesting field, but on the other hand it’s been stimulating to dig into new fields with an ‘outside’ view.

Dave Powers
Since working with Jim at Genentech in the 1980’s, I returned to school for my PhD (University of Medicine and Dentistry of New Jersey),  did a postdoc with Jim Marks at UCSF and have been knocking around the biotech/pharma industry ever since (Eos Biotechnology, Protein Design Labs, Facet Biotech, Abbott/Abbvie). Currently a Research Fellow at Abbvie, leading up our West Coast Biologics group in Redwood City in charge of antibody discovery (phage and hybridoma), antibody engineering, and research-scale protein production.